Phase 3 PEACHTREE, AZALEA integrated study results: BCVA gains, CST reduction associated with suprachoirodal injection
2-year results of YOSEMITE and RHINE: Faricimab remains noninferior to aflibercept with extended dosing schedule
OPT-302 combination therapy with ranibizumab for PCV shows VA gains, anatomic improvements in phase 2b trial